Disclosure:
Dr. Ramsay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Sunovion Pharmaceuticals Inc., Eisai, and Allied Group of Companies. Dr. Ramsay has received research support from Marinus, Sage, Sunovion Pharmaceuticals Inc., Eisai, and Lundbeck.

The IPANEMA Study: Top Line Results from an Investigator-Initiated Multi-site Late-onset Pompe Disease Prevalence Study

Disclosure:
Dr. Wencel has nothing to disclose.

Epilepsy: Antiseizure Medications III

Start Time

Pub.

Title

Presenter

11:30 AM

005

Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome in an Open-Label Extension Trial

Disclosure:
Dr. Halford has received personal compensation for consulting from GW Pharma and NCGS. Dr. Halford has received research support from Takeda, GW Pharma, SK Life Sciences, The Epilepsy Study Consortium, Brain Sentinel, and Philips.

A Pilot Study of Right Cerebellar tDCS as a Therapeutic Adjuvant in Chronic Aphasia after Left-Hemisphere Stroke

Disclosure:
Dr. Dvorak has nothing to disclose.

Aging and Dementia/Behavioral and Cognitive Neurology ePoster Session

Start Time

Pub.

Title

Presenter

11:30 AM

006

A Care Pathway for Post-Stroke Spatial Neglect: Initial Analysis of a Practice-Based Rehabilitation Research Network

Disclosure:
Dr. Barrett has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with emedicine/WebMD. Dr. Barrett has received research support from Dart Neuroscience and Brightcloud International funded research projects she led through the Kessler Foundation.

Disclosure:
Dr. Finkelstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prana Biotechnology. Dr. Finkelstein has received research support from Prana Biotechnology.

Bacteria, Fungi, and Prions

Start Time

Pub.

Title

Presenter

11:30 AM

006

Late-Onset Austrian Syndrome in a Patient with Bacterial Meningitis

Disclosure:
Dr. Shapouran has nothing to disclose.

Headache

Start Time

Pub.

Title

Presenter

11:30 AM

007

One and Done: A Case Series of Large Volume Occipital Nerve Blocks for the Treatment of Occipital Neuralgia

Disclosure:
Dr. Mathew has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Avanir, Teva, Biomobie staff, Amgen, Allergan, Promius, and Takeda.. Dr. Mathew has received personal compensation in an editorial capacity for Practical Neurology. Dr. Mathew has received research support from Biomobie.

Long-Term Efficacy of Dichlorphenamide for the Treatment of Primary Periodic Paralysis (PPP)

Disclosure:
Dr. Johnson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron, Strongbridge, Vertex, Fulcrum, and AveXis. Dr. Johnson has received personal compensation in an editorial capacity for Continuum. Dr. Johnson has received royalty, license fees, or contractual rights payments from University of Rochester. Dr. Johnson has received research support from Acceleron, CSL Behring, Fulcrum, Vertex, and AveXis.

Disclosure:
Dr. Meador has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Epilepsy Study Consortium for Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, UCB Pharma and Vivus Pharmaceuticals. Dr. Meador has received research support from Sunovion.

Progression of Parkinson’s Disease: A Longitudinal MRI Study of Functional Brain Connectome in a Large Cohort of Patients

Disclosure:
Dr. Filippi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Merk-Serono, Novartis, Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in an editorial capacity for Journal of Neurology. Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Teva Pharmaceutical Industries, Roche.

Loss of Brain Iron is Linked to Disability in Multiple Sclerosis - The Difference Between Concentration and Mass of Iron

Disclosure:
Dr. Hagemeier has nothing to disclose.

Genetic Muscle Disorders II

Start Time

Pub.

Title

Presenter

11:30 AM

011

Carotid Artery Dissection in a Young Woman with Ullrich Congenital Muscular Dystrophy

Disclosure:
Dr. Said-Said has nothing to disclose.

Epilepsy: Antiseizure Medications III

Start Time

Pub.

Title

Presenter

11:30 AM

011

Time Course of Efficacy and Tolerability Outcomes With Adjunctive Brivaracetam in Adults: A Post Hoc Analysis

Disclosure:
Dr. Meador has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Epilepsy Study Consortium for Eisai, GW Pharmaceuticals, NeuroPace, Novartis, Supernus, Upsher-Smith Laboratories, UCB Pharma and Vivus Pharmaceuticals. Dr. Meador has received research support from Sunovion.

Disclosure:
Dr. Chung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ucb, Sunovion, Lundbeck, Eisai. Dr. Chung has received research support from Ucb, SK Life Sciences.

Microstructure alterations in the midbrain of Parkinson’s patients: a multishell diffusion MRI study

Disclosure:
Dr. Chen has nothing to disclose.

Bacteria, Fungi, and Prions

Start Time

Pub.

Title

Presenter

11:30 AM

014

A Case of Neurobrucellosis in a non-endemic area

Disclosure:
Dr. Bronstein has nothing to disclose.

Headache

Start Time

Pub.

Title

Presenter

11:30 AM

015

Acute and preventive treatment patterns in episodic cluster headache: findings from the United States, United Kingdom and Germany

Disclosure:
Dr. Nichols has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Nichols holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Nichols was involved as an investigator. Dr. Nichols holds stock and/or stock options in Eli Lilly and Company.

Disclosure:
Dr. Lowes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Inc., Bristol Meyers-Squibb, Pfizer, and Sarepta Therapeutics. Dr. Lowes has received research support from Novartis and Sarepta Therapeutics.

Assessment of Deep Medullary Veins on 3T MRI in a Population-based Cohort

Disclosure:
Dr. Ao has nothing to disclose.

MS Metrics of Prognosis and Disease Progression

Start Time

Pub.

Title

Presenter

11:30 AM

017

Serum GFAP Associates with Neurofilament Light and Disease Severity in Late Multiple Sclerosis

Disclosure:
Dr. Airas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche, Merck . Dr. Airas has received research support from Sanofi-Genzyme.

Disclosure:
Dr. Andrews has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Andrews holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Andrews was involved as an investigator. Dr. Andrews holds stock and/or stock options in Eli Lilly and Company.

Neuroimaging: Aging, Vascular and Other

Start Time

Pub.

Title

Presenter

11:30 AM

019

Cognition predicted by brain biomarkers and demographic factors

Disclosure:
Dr. Tsapanou has nothing to disclose.

MS Metrics of Prognosis and Disease Progression

Start Time

Pub.

Title

Presenter

11:30 AM

019

Late onset MS is associated with more severe longitudinal development of central brain atrophy compared to adult onset MS

Disclosure:
Dr. Dujmic has nothing to disclose.

Intracerebral Aneursym and Other Neurovascular Malformations

Start Time

Pub.

Title

Presenter

11:30 AM

019

Life Expectancy in Familial Cerebral Cavernous Malformation: An Analysis of Prospective Database

Burden of Spasticity Among Patients and Caregivers: Results of a Multinational Survey

Disclosure:
Dr. Patel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz and Allergan. Dr. Patel has received research support from Allergan, Merz, and Ipsen.

Disclosure:
Dr. Mechtler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Promius, Allergan, Avanir, Amgen, Boston Biomedical, electroCore, Alder Biopharmaceuticals, Lilly. Dr. Mechtler has received research support from Dent Family Foundation.

Neuroimaging: Aging, Vascular and Other

Start Time

Pub.

Title

Presenter

11:30 AM

020

Increased Activity in Functional Brain Network among the Elderly with Youthful Memory in Superaging

Patient selection and outcomes of placement of the Neuropace Responsive Neurostimulator for the treatment of intractable epilepsy: a single center experience

Disclosure:
Dr. Agostini has nothing to disclose.

General Neurology: Neuroimaging and Disease

Start Time

Pub.

Title

Presenter

11:30 AM

029

Post-Mortem Neuroimaging in Amyotrophic Lateral Sclerosis

Disclosure:
Dr. Ishaque has nothing to disclose.

Parkinson's Disease Clinical Features and Clinical Care II

Start Time

Pub.

Title

Presenter

11:30 AM

029

Incidence and Predictors of 30 days readmission associated with Parkinson’s disease: 5-year National estimate (2010-2014)

Disclosure:
Dr. Singh has nothing to disclose.

Bacteria, Fungi, and Prions

Start Time

Pub.

Title

Presenter

11:30 AM

029

Sudden Death from Rupture of Cerebral Abscess into Subarachnoid Space

Disclosure:
Dr. Curran has nothing to disclose.

Neuroimaging: Alzheimer Disease

Start Time

Pub.

Title

Presenter

11:30 AM

030

Tracking Neurostructural Preclinical Predictors of Alzheimer’s Disease: Linking Clinical Markers to the Size of the Ventral Tegmental Area and Other Subcortical Nuclei

Disclosure:
Dr. De Marco has nothing to disclose.

MS Neuroimaging

Start Time

Pub.

Title

Presenter

11:30 AM

030

Inflammatory activity associated with increased rate of brain and retinal neuro-axonal injury in early MS The aim of this study is to address the effect of local inflammatory activity in brain and retinal neuro-axonal injury along MS course.

Disclosure:
Dr. Pulido Valdeolivas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche Spain, Genzyme-Sanofi, and Aura Innovative Robotics. Dr. Pulido Valdeolivas has received compensation for serving on the Board of Directors of Aura Innovative Robotics. Dr. Pulido Valdeolivas has received royalty, license fees, or contractual rights payments from Aura Innovative Robotics. Dr. Pulido Valdeolivas holds stock and/or stock options in Aura Innovative Robotics which sponsored research in which Dr. Pulido Valdeolivas was involved as an investigator. Dr. Pulido Valdeolivas holds stock and/or stock options in Aura Innovative Robotics. Dr. Pulido Valdeolivas has received research support from Aura Innovative Robotics.

Intracerebral Aneursym and Other Neurovascular Malformations

Start Time

Pub.

Title

Presenter

11:30 AM

030

Impact of daughter vessel selection for stent deployment on the recanalization rates of bifurcation aneurysms treated with single stent-assisted coiling (SAC)

Disclosure:
Dr. Saied has nothing to disclose.

Neuromuscular Junction Disorders

Start Time

Pub.

Title

Presenter

11:30 AM

030

Are the choices of Therapeutic options for the Management of Myasthenia Gravis Crisis with acute respiratory failure-Influenced by the patient’s Age. A New York State Planning and Research Cooperation System Database Analysis (1998-2014)

Disclosure:
Dr. Seyman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen-Idec. Dr. Seyman has received research support from Novartis.

Disclosure:
Dr. Antonini has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia, Sunovion, UCB, Boston Scientific, Angelini, Medtronic, GE, Boehringer Ingelheim, AbbVie, Zambon. Dr. Antonini has received research support from Mundipharma.

Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy

Start Time

Pub.

Title

Presenter

11:30 AM

040

Mortality and Long Term Outcome after Spontaneous Intracerebral Hemorrhage

"Tell me with whom you walk, and I will tell you who you are”: A Social Network Analysis of Adolescents with ADHD

Disclosure:
Dr. Arruda has nothing to disclose.

Parkinson's Disease Clinical Features and Clinical Care II

Start Time

Pub.

Title

Presenter

11:30 AM

041

Molecular and Genetic Characterization of Parkinson’s Disease: A Center-Wide Approach.

Disclosure:
Dr. Tropea has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Medtronics. Dr. Tropea has received research support from Sanofi.

Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy

Start Time

Pub.

Title

Presenter

11:30 AM

042

Role of Anti-Platelets & Anti-coagulants in Intracerebral hemorrhage: Analysis of a Large National Database

Disclosure:
Dr. Suriya has nothing to disclose.

Neurocritical Care: Subarachnoid Hemorrhage

Start Time

Pub.

Title

Presenter

11:30 AM

042

Variability In Reported Physician Practices For Brain Death Determination

A Prospective Open-label Trial of Long-Acting Liquid Methylphenidate for the Treatment of Attention Deficit/Hyperactivity Disorder in Intellectually Capable Adults with Autism Spectrum Disorder

Disclosure:
Dr. Joshi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Governor's Council for Medical Research and Treatment of Autism, The Israeli Society for ADHD, Canadian Academy of Child and Adolescent Psychiatry, University of Juelich. Dr. Joshi has received personal compensation in an editorial capacity for NIMH. Dr. Joshi has received research support from Pfizer Inc., F. Hoffmann-La Roche Ltd., NIH-NIMH, Simons Center for the Social Brain.

Parkinson's Disease Clinical Features and Clinical Care II

Start Time

Pub.

Title

Presenter

11:30 AM

044

Jumping as a Strategy to Overcome Freezing of Gait while Turning in Parkinson’s Disease

Disclosure:
Dr. Lizarraga has nothing to disclose.

Intracerebral Hemorrhage and Cerebral Amyloid Angiopathy

Start Time

Pub.

Title

Presenter

11:30 AM

045

Validation of ICH and ICH-GS scores in cohort of Indian patients with Intracerebral hemorrhage

Disclosure:
Dr. Dwyer has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Serono Novartis and Claret Medical. Dr. Dwyer has received research support from Novartis and Celgene.

Child Neurology: Autism and Behavioral Neurology

Start Time

Pub.

Title

Presenter

11:30 AM

045

Disparities in the Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents - a Nationwide Study

Novel Research Initiatives for Early Recognition and Comprehensive Management of Autism Spectrum Disorder to Empower Health Professionals and Health Care Providers: Two Decade Experience from a Tertiary Care Centre in India

Disclosure:
Dr. Panda has nothing to disclose.

Parkinson's Disease Clinical Features and Clinical Care II

Start Time

Pub.

Title

Presenter

11:30 AM

046

Vitamin D Assessment in Veterans with Parkinson’s Disease

Disclosure:
Dr. Jamal has nothing to disclose.

Neurocritical Care: Subarachnoid Hemorrhage

Start Time

Pub.

Title

Presenter

11:30 AM

047

Role of Glycemic Burden and Glycemic Burden Variability in Determination of Temporary and Permanent Cerebrospinal Fluid diversion after Aneurysmal Subarachnoid Hemorrhage

Disclosure:
Dr. Muzammil has nothing to disclose.

MS Neuroimaging

Start Time

Pub.

Title

Presenter

11:30 AM

047

Dynamics of Pseudo-Atrophy in RRMS Patients Treated with Interferon beta-1a as Assessed by Monthly Brain MRI

Evolution of Dietary Therapies in Treatment of Childhood Drug Resistant Epilepsy: an overview of nine studies including six randomized controlled trials accomplished over last twelve years in a tertiary care teaching hospital in North India

Disclosure:
Dr. Gulati has nothing to disclose.

Neurocritical Care: Brain Death and Traumatic Brain Injury

Start Time

Pub.

Title

Presenter

11:30 AM

052

End of Life Preferences: Medical Students’ Attitudes Toward Life Support

Disclosure:
Dr. Zhong has nothing to disclose.

MS Neuroimaging

Start Time

Pub.

Title

Presenter

11:30 AM

053

Changes in Brain Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients

Disclosure:
Dr. Dwyer has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Serono Novartis and Claret Medical. Dr. Dwyer has received research support from Novartis and Celgene.

Transcranial Doppler-detected Microembolic Signals as a Predictor of New Brain Ischemic Lesion after Elective Coronary Intervention

Disclosure:
Dr. Herzig has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer. Dr. Herzig has received personal compensation in an editorial capacity for Ambit Media.

Injury in Developing Brain: Fetal Neurology, Trauma and Stroke

Start Time

Pub.

Title

Presenter

11:30 AM

060

Neurologic Sequelae of Infective Endocarditis in Children

Disclosure:
Dr. Favilla has nothing to disclose.

Practice, Policy, and Ethics II

Start Time

Pub.

Title

Presenter

11:30 AM

061

Impact of doing Echocardiogram and Brain Magnetic Resonance Imaging on Length of Stay and Hospital Charges in Transient Ischemic Attack Patients in United States: Analysis of Nationwide Inpatient Sample 2006-2014

Disclosure:
Dr. Raji has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Serono, Genzyme, Novartis. Dr. Raji has received research support from Genzyme.

Strengthening knowledge when data are scarce: the role of social media after AFM.

Disclosure:
Dr. Bove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche Genentech, Novartis, EMD Serono, Biogen, Sanofi Genzyme, and Pear Digital. Dr. Bove has received research support from Akili Interactive.

Practice, Policy, and Ethics II

Start Time

Pub.

Title

Presenter

11:30 AM

067

Transition of Care from Child to Adult Neurologists: Implementation and Financial Strategies for Child and Adult Neurologists

Disclosure:
Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stealth Biotheraputics, Modis (aka Meves) Pharmaceuticals, NeuroVive, MitoBridge, AAN for CPT Consulting and Educational Activities. Dr. Cohen has received research support from Dr. Cohen has received research support from Stealth Biotherapeutics, BioElectron Technologies.

MS Neuroimaging

Start Time

Pub.

Title

Presenter

11:30 AM

067

Short-term MRI-based Prediction of Clinical MS Progression in a Real World Setting

Disclosure:
Dr. Van Hecke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with icometrix.

Non-invasive Longitudinal Assessment of Cerebrovascular Reactivity after TBI using functional Near Infrared Spectroscopy

Disclosure:
Dr. Sangobowale has nothing to disclose.

Child Neurology: Neuromuscular Disease: Birth to Adulthood II

Start Time

Pub.

Title

Presenter

11:30 AM

069

Early onset congenital myopathies and LGMD phenotype investigated by muscle MRI in two trasportinopathy families

Disclosure:
Dr. Marozzo has nothing to disclose.

Practice, Policy, and Ethics II

Start Time

Pub.

Title

Presenter

11:30 AM

070

Contribution towards Public Health Awareness Activities and Continuing Medical education for Empowering Health Care Professionals on Childhood Neurodevelopmental Disorders: Experience of a Tertiary Care Teaching Hospital in North India over the last decade-Going E-way

Effects of a novel practice model on medical team burnout in an academic neurology practice

Disclosure:
Dr. Kern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Pharmaceuticals, Merz Pharma and SAI-Med Partners, LLC.

Immunotherapies: New Targets and Side Effects

Start Time

Pub.

Title

Presenter

11:30 AM

076

Analysis of Relapse by MRC Sum Score in the PATH Study of Subcutaneous Immunoglobulin in CIDP

Disclosure:
Dr. Bril has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with CSL Behring UCB Alnylam Argenx Alexion Grifols Octapharma Shire (Takeda) Pfizer and PowellMansfield. Dr. Bril has received research support from CSL Behring UCB Grifols Argenx Biogen and Octapharma.

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration

Disclosure:
Dr. Collins has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roivant Sciences, Inc; Immunovant, Inc.

11:30 AM

080

Changes in Concomitant Immunosuppressive Therapy Use During a Phase 3 Open-label Study of Eculizumab in Adults with Generalized Myasthenia Gravis: an Interim Analysis

Disclosure:
Dr. Nowak has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Ra Pharma, Momenta, Grifols, Roivant. Dr. Nowak has received research support from Alexion, Ra Pharma, Genentech, Grifols.

Disclosure:
Dr. Cameron has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adamas Corporation and GW Pharmaceuticals. Dr. Cameron has received personal compensation in an editorial capacity for Current Neurology and Neuroscience Reports.

11:30 AM

088

Which treatments improve fatigue and quality of life in Multiple Sclerosis? Evidence appraisal and development of visual interactive evidence maps

Disclosure:
Dr. Tsou has nothing to disclose.

11:30 AM

089

Sexual Dysfunction in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Prevalence

Disclosure:
Dr. Kim has nothing to disclose.

11:30 AM

090

Interoception as a neurocognitive mechanism underlying fatigue in Multiple Sclerosis

Disclosure:
Dr. Gonzalez Campo has nothing to disclose.

11:30 AM

091

Origins of Fatigue in an Early Multiple Sclerosis Cohort

Disclosure:
Dr. Marino has nothing to disclose.

11:30 AM

092

A Survey of Cannabis-Based Product Use in Multiple Sclerosis Patients at the University of British Columbia Hospital

Disclosure:
Dr. Wingerchuk has received personal compensation from MedImmune, Celgene, Novartis Dr. Wingerchuk has received personal compensation in an editorial capacity as co-Editor-in-Chief for The Neurologist. Dr. Wingerchuk has received research support from Alexion and TerumoBCT.